Background: Robotic or endoscopic thyroidectomy using bilateral axillo-breast approach (BABA) is frequently performed for excellent cosmesis. However, postoperative pain is remained as concerns due to the extent tissue dissection and tension during the operation. Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that reduces acute postoperative pain. We evaluated the effects of intraoperative ketamine infusion on postoperative pain control and recovery profiles following BABA robotic or endoscopic thyroidectomy.
Introduction
Endoscopic techniques have revolutionized many fields of surgery. In particular, robotic and endoscopic thyroidectomy has gained popularity for the treatment of thyroid disease over the past few decades due to markedly improved cosmetic satisfaction. [1] Compared to conventional open thyroidectomy, the bilateral axillo-breast approach (BABA) robotic or endoscopic thyroidectomy offers superior aesthetic results, as no scar is left on the anterior neck area. [2] However, large flap dissection of the anterior chest and cervical area and significant tension in the tissue flap due to insufflation with CO 2 is required to obtain a satisfactory view during the surgery. It has been reported that patients who undergo endoscopic or robotic surgery on the neck or thyroid suffer from moderate to severe neck, anterior chest, and axillary pain following surgery. [1, 3] In addition, about 70% of patients complain of anterior chest discomfort within 4 days after endoscopic thyroidectomy, [4] and hypoesthesia with discomfort to the anterior chest area may persist for 3 months following surgery. [5] Postoperative pain is associated with reduced quality of recovery, delayed mobilization, prolonged hospitalization, and the development of chronic pain syndrome. Acute pain control following BABA robotic or endoscopic thyroidectomy is essential for quality of recovery and to prevent chronic pain. [5] Opioids are the first-line postoperative analgesia; however, the high incidence of postoperative nausea and vomiting (PONV) limits their use following thyroidectomy. [6] Several trials with nonopioid analgesics have been carried out for the management of acute pain following BABA robotic or endoscopic thyroidectomy. [7] [8] [9] In one study, perioperative administration of intravenous paracetamol was effective for pain management in patients with robot-assisted thyroidectomy performed via the transaxillary approach; however, this required infusion over 24 hours. [7] In another study, pregabalin was administered from the day before surgery to 2 days postoperatively in patients who had undergone robot-assisted thyroidectomy; this was effective for reducing early postoperative pain, but in some cases led to dizziness and sedation. [8] Ryu et al [9] investigated the effects of spraying 0.25% levobupivacaine on the dissected area, and reported reduced pain in the anterior chest region for 2 days postoperatively following BABA robotic thyroidectomy. The use of nonsteroidal antiinflammatory drugs (NSAIDs) as a systemic analgesic should be avoided due to the increased risk of bleeding complications, [10] which may lead to fatal airway obstruction following thyroidectomy; however, the clinical impact of NSAIDs on postoperative bleeding remains unclear.
Ketamine is a phencyclidine derivative, and was first developed as a general anesthetic in the 1960s. [11] It also acts as a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, which reduces acute postoperative pain and prevents the development of chronic postoperative pain. [11] It may be administered perioperatively for postoperative pain as an adjuvant to systemic opioids, with fewer adverse effects [12] ; however, the effects of perioperative ketamine infusion on postoperative pain following BABA robotic or endoscopic thyroidectomy have not been investigated. We hypothesized that low doses of ketamine infused during surgery would reduce postoperative pain. This randomized, double-blinded, placebocontrolled study investigated the effects of perioperative ketamine infusion on acute postoperative pain and recovery profiles in patients who underwent BABA robotic or endoscopic thyroidectomy.
Methods

Protocol and patients
The Institutional Review Board of Seoul National University Bundang Hospital (B-15.9/314-009) approved this prospective, randomized, and double-blinded controlled trail and the protocol was registered at http://cris.nih.go.kr (registration number KCT0001887). Written informed consent was obtained from all patients. A total of 58 patients, American Society of Anesthesiologists (ASA) physical status I or II, 19 to 69 years of age, scheduled for elective BABA robotic or endoscopic thyroidectomy from November 2015 to June 2016 were enrolled for this study.
Inclusion criteria are thyroid mass smaller than 4 cm in benign cases and smaller than 2 cm in potentially malignant cases without evidence of extracapsular soft tissue invasion or metastasis. Exclusion criteria are patients with a history of chronic pain, allergy or hypersensitivity to ketamine, chronic use of analgesics or opioids for >2 weeks before the surgery, previous history of surgery on chest or neck area and those who were not able to understand a numerical rating scale (NRS) were excluded.
Anesthesia
Patients were transferred to the operating room after midazolam premedication (0.03 mg/kg). On arrival at the operating room, patients were monitored with standard monitoring including electrocardiography, noninvasive arterial pressure, and pulse oximetry. Total intravenous anesthesia with propofol and remifentanil was used for the induction and maintenance of anesthesia using an Orchestra infusion pump system (Fresenius vial, Brezins, France) to maintain bispectral index monitoring (A-2000 BIS TM monitor; Aspect Medical Systems, Inc., Natick, MA) between 40 and 60. Rocuronium bromide 0.6 mg/kg was injected to facilitate muscle relaxation and additional doses of rocuronium bromide 0.15 mg/kg was administered during operation to maintain 1 to 2 twitches on train-of-four stimulation of ulnar nerve. The ventilator was set to maintain end-tidal CO 2 between 35 and 40 mm Hg with oxygen and medical air (FiO 2 0.5). After surgery, neuromuscular blockade was reversed with neostigmine 0.04 mg/kg and glycopyrrolate 0.01 mg/kg. Patients were extubated after they were fully recovered and transferred to the postanesthesia care unit (PACU).
Surgery
A single experienced surgeon (JYC) performed all the operations to maintain a uniform application of surgical stimulus. The operating procedures for endoscopic or robotic (with the aid of the da Vinci Robot System [Intuitive Surgical, Inc., Mountain View, CA]) assisted thyroidectomy using BABA approaches have been described previously. [9] Patients were placed in a supine position with a slight neck extension using a pillow under the shoulders. Skin flaps were outlined and 200 mL of 1:200,000 diluted epinephrine was injected along the upper chest and subplatysmal space for vasoconstriction. Then, 2 superomedial circumareolar marginal incisions (right, 1.2 cm; left, 0.8 cm) and 2 axillary skin incisions (0.8 cm each) were made for the instrumental ports. Flap dissections were initially carried out using endoscopic instruments and extended to the thyroid cartilage superiorly, 3 cm below the clavicle inferiorly, and laterally from just beyond the lateral border of one sternocleidomastoid muscle to the other. The surgical space was insufflated with CO 2 gas (pressure of 5-6 mm Hg) via the 12 mm camera port.
After docking of robot or endoscopic instruments, the midline was divided using monopolar electrocautery until the thyroid was visualized. The cricothyroid membrane, the isthmus, and the central group of lymph nodes were identified and then thyroid isthmus was routinely divided. The middle thyroid pedicle was then ligated and divided using harmonic shears. The remainder of the thyroidectomy was performed with identification of the middle and inferior thyroid pedicles, the recurrent laryngeal nerve, and the superior and inferior parathyroid glands. After unilateral thyroidectomy, the thyroid specimen was removed through the left axillary incision using an endoplastic bag. The contralateral lobe was dissected in a similar manner.
After thyroidectomy, antiadhesive solution (Guardix-SG, 6 g; Hanmi Pharmaceutical, Seoul, Korea) was sprayed onto the whole flap. One Jackson-Pratt drains were inserted through left axillary incision. A surgical brassiere was used to provide compression of the flaps. 
Randomization and intervention
Randomization was performed before the induction of anesthesia by an anesthesiologist who is only in charge of the randomization. A computer generated random number table (Random Allocation Software Version 1.0) with block size 4 was used. From a table of random numbers, patients were allocated to control group (n = 29) or ketamine group (n = 29). Patients, anesthesiologists responsible for the patients and outcome assessors were blinded to the group assignment. Study solutions (normal saline for control group or ketamine 1 mg/kg bolus, 60 m g/kg/h continuous infusion for ketamine group) were infused right after the induction of anesthesia by the anesthesiologist as identical syringes (50 mL) to ensure blinding until the end of surgery (skin closure).
Outcomes
The primary endpoint was the postoperative pain scores. Postoperative pain in each area (neck, axilla, and anterior chest) was evaluated by the patients on a 101-point NRS (0 = no pain, 100 = the worst imaginable pain) at 1, 6, 24, and 48 hours after surgery. Secondary endpoints were recovery profiles including postoperative rescue analgesics and adverse events. Patients were evaluated every 15 minutes using the modified Aldrete scoring system until ready for discharge from the PACU and the criterion used for patient discharge from PACU was the achievement of a modified Aldrete score of 9. [13] In the PACU, first-line rescue analgesic was fentanyl 50 mg and second-line was intravenously ketorolac tromethamin 30 mg if NRS is more than 30. After that, intravenous ketorolac tromethamin 15 mg was used as the rescue analgesics in the ward if NRS was more than 30 or the patient wanted the analgesic drug. Ketamine related adverse events such as sedation or diplopia were recorded if it occurred. In addition, postoperative adverse effects such as PONV, shivering, headache, dizziness, or drowsiness were also recorded during the study period.
Statistical analysis
Sample size calculation was based on mean pain scores of 6 (3.5) 1 hour after robot-assisted thyroidectomy [8] using G * power 3.0. We considered that a decrease of 2 in the mean pain scores would be clinically significant. Twenty-six patients per group were required (an alpha value of 0.05 and power of 80%) and a total of 58 patients were finally decided to be needed considering 10% drop-out rate.
Statistical analysis was performed using SPSS 21 (SPSS, Inc., Chicago, IL). The test of normal distribution was assessed with the Shapiro-Wilk test. Student t test was used to compare normally distributed variables (tumor size, resected thyroid weight, and discharge time), and the Mann-Whitney U test was used to compare not normally distributed continuous variables. Chi-square test or Fisher exact test was used for analysis of other categorical outcomes such as the incidences of rescue analgesics and adverse effects. A full analysis set was used for the analysis of data. All values presented are mean (standard deviation), median (interquartile range), or number of patients (%). P values <0.05 were considered statistically significant.
Results
Sixty-seven patients were screened for eligibility and 58 patients were randomized for the study. Of the 58 patients enrolled in the study, 1 patient was eliminated from the data collection and a total of 57 patients were included in the final analysis. One patient from ketamine was excluded after randomization for the patient controlled analgesia instead of rescue analgesics (Fig. 1) .
Clinical characteristics are summarized in Table 1 . Patient, surgery, and anesthetic characteristics were similar between the 2 groups (Table 1 ). There were 55 females and 2 males with mean age of 39 or 40. All surgeries were completed successfully and no cases were converted to open thyroidectomy. Forty-five fourteen patients were operated with robotic and endoscopic thyroidectomy, respectively. Postoperative pathology of the patients showed 45 patients with papillary carcinoma, 1 with follicular carcinoma, 5 with nodular hyperplasia, and 4 with follicular adenoma. There were no significant differences in tumor size or pathologic type between the 2 groups.
Postoperative pain scores were evaluated in each area of the surgery (neck, axilla, and chest) using 101 NRS at postoperative 1, 6, 24, and 48 hours. There are statistically significant differences in pain scores between control and ketamine group during postoperative 48 hours although pain scores at postoperative 1 hour were not different between the 2 groups. Pain scores of the ketamine group were significantly lower than those of control group in the neck area at 6 hours (30 [30] vs 50 [30]; P = 0.017), 24 hours (20 [10] vs 30 [20] ; P < 0.001), and 48 hours (10 [10] vs 20 [15] ; P = 0.005) postoperatively (Fig. 2) . Patients in ketamine group showed lower pain scores in the axilla area than those in control group at postoperative 24 hours (15 [27] vs 30 [20] ; P = 0.024) and 48 hours (10 [20] vs 20 [20] ; P = 0.005) (Fig. 2) . Pain in the chest area of the ketamine group was lower than control group at postoperative 48 hours (10 [10] vs 20 [20] ; P = 0.007) (Fig. 2 ).
There were no statistically significant differences in the need of rescue analgesics between the 2 groups ( Table 2 ). The total numbers of rescue analgesic administration were smaller in ketamine group than in control group during the study period though they could not reach statistically significant differences (1.5 [1] vs 2 [2] ; P = 0.051) ( Table 2) .
Discharge times from PACU were similar between the 2 groups (Table 3) . Major complication related with ketamine infusion did not occur in this study. Postoperative adverse events including PONV, headache, dizziness, and shivering were recorded during the study period and there were no significant differences in postoperative complications between the 2 groups (Table 3 ).
Discussion
We set out this prospective, randomized, and controlled trial to determine whether intraoperative ketamine infusion would decrease postoperative pain following BABA robotic or endoscopic thyroidectomy. The principal finding was that low-dose ketamine infusion during anesthesia significantly reduced postoperative pain, with no increased incidence of adverse events.
During BABA robotic or endoscopic thyroidectomy, a subplatysmal skin flap is dissected from the axilla to the anterior neck, and forcefully lifted to enable visualization of the surgical space. [14] To expose the thyroid, the dissected area is wider during robotic or endoscopic thyroidectomy than with conventional open thyroidectomy, which explains the significant postoperative pain following robotic or endoscopic thyroidectomy. [14] BABA leads to additional operative trauma along the route to the thyroid; therefore, this technique may be expected to result in greater postoperative pain compared to conventional open thyroidectomy. [15] In this study, a subanesthetic dose of ketamine was infused intravenously. The postoperative pain Kim et com scores in the neck, axilla, and chest area were significantly lower in the ketamine group than in the control group during the first 48 hours postoperatively. Pain scores at 1 hour postoperatively did not differ between the 2 groups in all areas; however, this can be explained by considering the residual anesthetic effect. Ketamine is a noncompetitive NMDA receptor antagonist related to pain sensitivity, and has been administered during various kinds of surgery for postoperative pain control. [16] Preemptive analgesia can prevent the development and establishment of the central processing of noxious stimulation (i.e., surgical incision) during the pain pathway. [17] In this study, a subanesthetic dose of ketamine (1 mg/kg bolus, 60 mg/kg/h continuous infusion) was infused immediately following induction of anesthesia (before the surgical incision), and was retained until the end of the surgery. The optimal dose and infusion timing of ketamine for postoperative pain control has not yet been established; however, most trials have used ketamine in subanesthetic doses during the perioperative period.
[18] Reviews and meta-analyses that have evaluated the preemptive analgesic effects of ketamine for postoperative pain have concluded that subanesthetic doses of ketamine (0.15-0.5 mg/kg bolus, 60-120 mg/kg/h continuous infusion) result in preemptive analgesic effects that can reduce postoperative opioid usage with no adverse effects. [12, 18] There were no statistically significant differences in the requirement for rescue analgesics between the 2 groups, although the total number of administrations of rescue analgesics was smaller in the ketamine group than in the control group. Rescue analgesics were used in preference to opioid-based patient control analgesia, because the most distressing obstacle during postoperative pain management for thyroidectomy patients is PONV due to the routine use of opioids. Moreover, the incidence of PONV following thyroidectomy appears to be higher than with other surgeries. [18] No major complications were associated with ketamine infusion, consistent with the results of a review on the use of ketamine for postoperative analgesia. [12] The recovery time (discharge time from PACU) and incidence of postoperative adverse effects did not differ between the 2 groups. Two patients in the control group and 7 in the ketamine group exhibited PONV, although this difference was not statistically significant. No trials have provided extractable data regarding the effects of ketamine on PONV, because PONV has not been the primary outcome of pain control studies. Intraoperative ketamine infusion has not been shown to reduce PONV, and may even have a negative effect on the severity of nausea following lumbar spinal surgery. [19] However, a reduction in PONV has been reported with ketamine usage because of the reduced opioid dosage it enables. [20] In this study, there were no statistically significant differences in the requirement for rescue analgesics, including opioids and NSAIDs.
A major limitation of the present study is that the effects of ketamine infusion on acute postoperative pain were evaluated for only 2 days postoperatively, with no assessment of chronic pain. Acute pain control may be predictive of the development of longterm sensory disturbances or discomfort, and these chronic symptoms may persist for up to 3 months following robot or endoscopy-assisted thyroidectomy. [5] Tae et al [21] reported that postoperative anterior chest pain scores were higher following robotic thyroidectomy than after conventional open thyroidectomy for the first week postoperatively but that there was no difference between the 2 groups after 1 or 3 months. However, Song et al [5] found that anterior chest discomfort and sensory disturbance were greater and required longer recovery times following robotic thyroidectomy than did conventional open thyroidectomy. Therefore, ketamine may reduce the development of chronic postoperative pain via NMDA receptor blockade, which reduces wind-up and central sensitization. [11] 
Conclusion
This study addressed the efficacy and safety profiles of intraoperative ketamine infusion during for BABA robotic or endoscopic thyroidectomy. Ketamine in subanesthetic dose (1 mg/kg bolus, 60 mg/kg/h continuous infusion) may be a useful adjunct in that it reduced postoperative pain scores during postoperative 48 hours after BABA robotic or endoscopic thyroidectomy without adverse effect. Further studies on optimal dose of ketamine and the effect of intraoperative ketamine infusion on chronic postsurgical pain with long-term follow-up are needed.
